Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JW202313
- Development stage
- Phase 2
- Lead developer
- Jewim Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
**JW202313** is an investigational chemical drug formulated as an inhalation powder for maintenance treatment of chronic obstructive pulmonary disease. It is being developed by Jingwei Pharmaceutical as a high-complexity dry-powder inhalation product. Public trial records support clinical evaluation in healthy volunteers and in patients with chronic obstructive pulmonary disease, but the precise active ingredient composition and molecular target have not been publicly disclosed.
- Other names
- JW-202313JW202313JW 202313
02
Targets
CHRM3 (M3)
Beyond the preview
Go deeper on JW202313.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JW202313.